Effect of etanercept therapy on psoriasis symptoms in patients from Latin America, Central Europe, and Asia: A subset analysis of the PRISTINE trial

L. Kemeny, M. Amaya, P. Cetkovska, N. Rajatanavin, W. R. Lee, A. Szumski, L. Marshall, E. Y. Mahgoub, E. Aldinç

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Background: Psoriasis prevalence and characteristics in Asia, Central Europe, and Latin America have not been thoroughly investigated and there are no large trials for biologic treatments for patients from these regions. The goal of this analysis was to report clinical response to anti-tumor necrosis factor-alpha treatment in these patients. Methods: Patients from Argentina, Czech Republic, Hungary, Mexico, Taiwan, and Thailand (N = 171) were included in this subset analysis of the PRISTINE trial. Patients with stable moderate-to-severe plaque psoriasis were blinded and randomized to receive etanercept 50 mg once weekly (QW) or biweekly (BIW) for 12 weeks, followed by 12 weeks of open-label QW treatment with etanercept 50 mg through week 24 (QW/QW vs. BIW/QW). Concomitant methotrexate (≤20 mg/week) and mild topical corticosteroids or other agents were permitted at the physician's discretion, in accordance with therapeutic practice. Results: As early as week 8, 26.7 % in the etanercept QW group and 44.0 % in the BIW group achieved Psoriasis Area and Severity Index (PASI) 75. At weeks 12 and 24, respectively, PASI 75 increased to 39.5 % and 62.8 % in the QW/QW group and 66.7 % and 83.3 % in the BIW/QW group. PASI 75 was significantly different between treatment groups from week 8 through the end of study (p <0.05). The Kaplan-Meier estimate of the proportions achieving PASI 75 in QW/QW and BIW/QW groups, respectively, was 27.4 % and 45.8 % through week 8; 41.9 % and 68.7 % through week 12; and 72.5 % and 95.2 % through week 24. Conclusions: Treatment with etanercept 50 mg provided rapid relief of psoriasis symptoms in patients from Asia, Central Europe, and Latin America. A more rapid response was observed in patients who received BIW treatment for the first 12 weeks which was sustained after reducing to QW dosing for the subsequent 12 weeks. Response rates were similar to those observed in the overall PRISTINE population. Trial registration: ClinicalTrials.gov identifier NCT00663052

Original languageEnglish
Article number9
JournalBMC Dermatology
Volume15
Issue number1
DOIs
Publication statusPublished - May 21 2015

Fingerprint

Central Asia
Latin America
Psoriasis
Central America
Therapeutics
Hungary
Czech Republic
Argentina
Kaplan-Meier Estimate
Thailand
Mexico
Etanercept
Taiwan
Methotrexate
Adrenal Cortex Hormones
Tumor Necrosis Factor-alpha
Physicians

Keywords

  • Asia
  • Central Europe
  • Etanercept
  • Latin America
  • Psoriasis treatment

ASJC Scopus subject areas

  • Dermatology

Cite this

Effect of etanercept therapy on psoriasis symptoms in patients from Latin America, Central Europe, and Asia : A subset analysis of the PRISTINE trial. / Kemeny, L.; Amaya, M.; Cetkovska, P.; Rajatanavin, N.; Lee, W. R.; Szumski, A.; Marshall, L.; Mahgoub, E. Y.; Aldinç, E.

In: BMC Dermatology, Vol. 15, No. 1, 9, 21.05.2015.

Research output: Contribution to journalArticle

Kemeny, L. ; Amaya, M. ; Cetkovska, P. ; Rajatanavin, N. ; Lee, W. R. ; Szumski, A. ; Marshall, L. ; Mahgoub, E. Y. ; Aldinç, E. / Effect of etanercept therapy on psoriasis symptoms in patients from Latin America, Central Europe, and Asia : A subset analysis of the PRISTINE trial. In: BMC Dermatology. 2015 ; Vol. 15, No. 1.
@article{5308deb8dbd34097964464b15197068a,
title = "Effect of etanercept therapy on psoriasis symptoms in patients from Latin America, Central Europe, and Asia: A subset analysis of the PRISTINE trial",
abstract = "Background: Psoriasis prevalence and characteristics in Asia, Central Europe, and Latin America have not been thoroughly investigated and there are no large trials for biologic treatments for patients from these regions. The goal of this analysis was to report clinical response to anti-tumor necrosis factor-alpha treatment in these patients. Methods: Patients from Argentina, Czech Republic, Hungary, Mexico, Taiwan, and Thailand (N = 171) were included in this subset analysis of the PRISTINE trial. Patients with stable moderate-to-severe plaque psoriasis were blinded and randomized to receive etanercept 50 mg once weekly (QW) or biweekly (BIW) for 12 weeks, followed by 12 weeks of open-label QW treatment with etanercept 50 mg through week 24 (QW/QW vs. BIW/QW). Concomitant methotrexate (≤20 mg/week) and mild topical corticosteroids or other agents were permitted at the physician's discretion, in accordance with therapeutic practice. Results: As early as week 8, 26.7 {\%} in the etanercept QW group and 44.0 {\%} in the BIW group achieved Psoriasis Area and Severity Index (PASI) 75. At weeks 12 and 24, respectively, PASI 75 increased to 39.5 {\%} and 62.8 {\%} in the QW/QW group and 66.7 {\%} and 83.3 {\%} in the BIW/QW group. PASI 75 was significantly different between treatment groups from week 8 through the end of study (p <0.05). The Kaplan-Meier estimate of the proportions achieving PASI 75 in QW/QW and BIW/QW groups, respectively, was 27.4 {\%} and 45.8 {\%} through week 8; 41.9 {\%} and 68.7 {\%} through week 12; and 72.5 {\%} and 95.2 {\%} through week 24. Conclusions: Treatment with etanercept 50 mg provided rapid relief of psoriasis symptoms in patients from Asia, Central Europe, and Latin America. A more rapid response was observed in patients who received BIW treatment for the first 12 weeks which was sustained after reducing to QW dosing for the subsequent 12 weeks. Response rates were similar to those observed in the overall PRISTINE population. Trial registration: ClinicalTrials.gov identifier NCT00663052",
keywords = "Asia, Central Europe, Etanercept, Latin America, Psoriasis treatment",
author = "L. Kemeny and M. Amaya and P. Cetkovska and N. Rajatanavin and Lee, {W. R.} and A. Szumski and L. Marshall and Mahgoub, {E. Y.} and E. Aldin{\cc}",
year = "2015",
month = "5",
day = "21",
doi = "10.1186/s12895-015-0028-8",
language = "English",
volume = "15",
journal = "BMC Dermatology",
issn = "1471-5945",
publisher = "BioMed Central",
number = "1",

}

TY - JOUR

T1 - Effect of etanercept therapy on psoriasis symptoms in patients from Latin America, Central Europe, and Asia

T2 - A subset analysis of the PRISTINE trial

AU - Kemeny, L.

AU - Amaya, M.

AU - Cetkovska, P.

AU - Rajatanavin, N.

AU - Lee, W. R.

AU - Szumski, A.

AU - Marshall, L.

AU - Mahgoub, E. Y.

AU - Aldinç, E.

PY - 2015/5/21

Y1 - 2015/5/21

N2 - Background: Psoriasis prevalence and characteristics in Asia, Central Europe, and Latin America have not been thoroughly investigated and there are no large trials for biologic treatments for patients from these regions. The goal of this analysis was to report clinical response to anti-tumor necrosis factor-alpha treatment in these patients. Methods: Patients from Argentina, Czech Republic, Hungary, Mexico, Taiwan, and Thailand (N = 171) were included in this subset analysis of the PRISTINE trial. Patients with stable moderate-to-severe plaque psoriasis were blinded and randomized to receive etanercept 50 mg once weekly (QW) or biweekly (BIW) for 12 weeks, followed by 12 weeks of open-label QW treatment with etanercept 50 mg through week 24 (QW/QW vs. BIW/QW). Concomitant methotrexate (≤20 mg/week) and mild topical corticosteroids or other agents were permitted at the physician's discretion, in accordance with therapeutic practice. Results: As early as week 8, 26.7 % in the etanercept QW group and 44.0 % in the BIW group achieved Psoriasis Area and Severity Index (PASI) 75. At weeks 12 and 24, respectively, PASI 75 increased to 39.5 % and 62.8 % in the QW/QW group and 66.7 % and 83.3 % in the BIW/QW group. PASI 75 was significantly different between treatment groups from week 8 through the end of study (p <0.05). The Kaplan-Meier estimate of the proportions achieving PASI 75 in QW/QW and BIW/QW groups, respectively, was 27.4 % and 45.8 % through week 8; 41.9 % and 68.7 % through week 12; and 72.5 % and 95.2 % through week 24. Conclusions: Treatment with etanercept 50 mg provided rapid relief of psoriasis symptoms in patients from Asia, Central Europe, and Latin America. A more rapid response was observed in patients who received BIW treatment for the first 12 weeks which was sustained after reducing to QW dosing for the subsequent 12 weeks. Response rates were similar to those observed in the overall PRISTINE population. Trial registration: ClinicalTrials.gov identifier NCT00663052

AB - Background: Psoriasis prevalence and characteristics in Asia, Central Europe, and Latin America have not been thoroughly investigated and there are no large trials for biologic treatments for patients from these regions. The goal of this analysis was to report clinical response to anti-tumor necrosis factor-alpha treatment in these patients. Methods: Patients from Argentina, Czech Republic, Hungary, Mexico, Taiwan, and Thailand (N = 171) were included in this subset analysis of the PRISTINE trial. Patients with stable moderate-to-severe plaque psoriasis were blinded and randomized to receive etanercept 50 mg once weekly (QW) or biweekly (BIW) for 12 weeks, followed by 12 weeks of open-label QW treatment with etanercept 50 mg through week 24 (QW/QW vs. BIW/QW). Concomitant methotrexate (≤20 mg/week) and mild topical corticosteroids or other agents were permitted at the physician's discretion, in accordance with therapeutic practice. Results: As early as week 8, 26.7 % in the etanercept QW group and 44.0 % in the BIW group achieved Psoriasis Area and Severity Index (PASI) 75. At weeks 12 and 24, respectively, PASI 75 increased to 39.5 % and 62.8 % in the QW/QW group and 66.7 % and 83.3 % in the BIW/QW group. PASI 75 was significantly different between treatment groups from week 8 through the end of study (p <0.05). The Kaplan-Meier estimate of the proportions achieving PASI 75 in QW/QW and BIW/QW groups, respectively, was 27.4 % and 45.8 % through week 8; 41.9 % and 68.7 % through week 12; and 72.5 % and 95.2 % through week 24. Conclusions: Treatment with etanercept 50 mg provided rapid relief of psoriasis symptoms in patients from Asia, Central Europe, and Latin America. A more rapid response was observed in patients who received BIW treatment for the first 12 weeks which was sustained after reducing to QW dosing for the subsequent 12 weeks. Response rates were similar to those observed in the overall PRISTINE population. Trial registration: ClinicalTrials.gov identifier NCT00663052

KW - Asia

KW - Central Europe

KW - Etanercept

KW - Latin America

KW - Psoriasis treatment

UR - http://www.scopus.com/inward/record.url?scp=84929580419&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84929580419&partnerID=8YFLogxK

U2 - 10.1186/s12895-015-0028-8

DO - 10.1186/s12895-015-0028-8

M3 - Article

C2 - 25994179

AN - SCOPUS:84929580419

VL - 15

JO - BMC Dermatology

JF - BMC Dermatology

SN - 1471-5945

IS - 1

M1 - 9

ER -